每日一次单吸入器莫米松-茚达特罗-格隆溴铵对比ICS-LABA治疗控制不佳哮喘(IRIDIUM)
IRIDIUM研究为52周随机双盲双模拟3期试验,纳入3092例控制不佳哮喘患者,比较每日一次单吸入器MF-IND-GLY与MF-IND或每日两次FLU-SAL。结果显示MF-IND-GLY显著改善谷FEV1,安全性各组均衡。
要点
- 中剂量和高剂量MF-IND-GLY较相应剂量MF-IND显著改善第26周谷FEV1。
- MF-IND-GLY两个剂量组谷FEV1改善均优于高剂量FLU-SAL。
- 各组不良事件发生率总体均衡,死亡均与研究药物无关。
核心结论
- 每日一次单吸入器MF-IND-GLY较ICS-LABA组合(MF-IND和FLU-SAL)改善控制不佳哮喘患者的肺功能。
- MF-IND-GLY安全性特征与各治疗组相似。
- MF-IND-GLY因此成为这类患者的一个良好治疗选择。
研究设计与样本
- 52周、双盲、双模拟、平行组、活性对照3期研究,从41个国家415个中心招募患者。
- 纳入18至75岁、接受中剂量或高剂量ICS-LABA仍症状性哮喘、前一年至少一次急性加重、FEV1占预计值百分比低于80%的患者。
- 3092例患者随机分配(1:1:1:1:1)至中剂量MF-IND-GLY(n=620)、高剂量MF-IND-GLY(n=619)、中剂量MF-IND(n=617)、高剂量MF-IND(n=618)或高剂量FLU-SAL(n=618)。
- 主要结局为第26周全分析集患者MF-IND-GLY对比MF-IND的谷FEV1自基线变化,采用重复测量混合模型分析。
- 安全性在所有至少接受一剂研究药物的患者中评估。
主要发现
- 研究期间报告7例死亡(中剂量MF-IND-GLY 1例、高剂量MF-IND-GLY 2例、高剂量MF-IND 4例),研究者认为均非研究药物或其他研究相关因素所致。
关键数值与推荐
- 主要疗效标准:第26周谷FEV1自基线变化,MF-IND-GLY对比MF-IND。
- 中剂量MF-IND-GLY(80 μg, 150 μg, 50 μg)每日一次经Breezhaler吸入。
- 高剂量MF-IND-GLY(160 μg, 150 μg, 50 μg)每日一次经Breezhaler吸入。
- 高剂量FLU-SAL(500 μg, 50 μg)每日两次经Diskus吸入。
临床怎么用
- 对于接受中剂量或高剂量ICS-LABA仍控制不佳、前一年有急性加重且FEV1占预计值低于80%的哮喘患者,可考虑每日一次单吸入器MF-IND-GLY。
- MF-IND-GLY较ICS-LABA组合可改善肺功能,安全性相似。
局限性
- 研究未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with asthma who are inadequately controlled on inhaled corticosteroid-long-acting β2-adrenoceptor agonist (ICS-LABA) combinations might benefit from the addition of a long-acting muscarinic receptor antagonist. The aim of the IRIDIUM study was to assess the efficacy and safety of a once-daily, single-inhaler combination of mometasone furoate, indacaterol acetate, and glycopyrronium bromide (MF-IND-GLY) versus ICS-LABA in patients with inadequately controlled asthma. METHODS: In this 52-week, double-blind, double-dummy, parallel-group, active-controlled phase 3 study, patients were recruited from 415 sites across 41 countries. Patients aged 18 to 75 years with symptomatic asthma despite treatment with medium-dose or high-dose ICS-LABA, at least one exacerbation in the previous year, and a percentage of predicted FEV1 of less than 80% were included. Enrolled patients were randomly assigned (1:1:1:1:1) via interactive response technology to receive medium-dose or high-dose MF-IND-GLY (80 μg, 150 μg, 50 μg; 160 μg, 150 μg, 50 μg) or MF-IND (160 μg, 150 μg; 320 μg, 150 μg) once daily via Breezhaler, or high-dose fluticasone-salmeterol (FLU-SAL; 500 μg, 50 μg) twice daily via Diskus. The primary outcome was change from baseline in trough FEV1 with MF-IND-GLY versus MF-IND at week 26 in patients in the full analysis set, analysed by means of a mixed model for repeated measures. Safety was assessed in all patients who received at least one dose of study drug. This study is registered with ClinicalTrials.gov, NCT02571777, and is completed. FINDINGS: Between Dec 8, 2015, and Jun 14, 2019, 3092 of 4851 patients screened were randomly assigned (medium-dose MF-IND-GLY, n=620; high-dose MF-IND-GLY, n=619; medium-dose MF-IND, n=617; high-dose MF-IND, n=618; high-dose FLU-SAL, n=618). 2747 (88·8%) patients completed the 52-week treatment and 321 (10·4%) started but discontinued study treatment prematurely. Medium-dose MF-IND-GLY (treatment difference [Δ] 76 mL [95% CI 41-111]; p<0·001) and high-dose MF-IND-GLY (Δ 65 mL [31-99]; p<0·001) showed superior improvement in trough FEV1 versus corresponding doses of MF-IND at week 26. Improvements in trough FEV1 were greater for both medium-dose MF-IND-GLY (99 mL [64-133]; p<0·001) and high-dose MF-IND-GLY (119 mL [85-154]; p<0·001) than for high-dose FLU-SAL at week 26. Overall, the incidence of adverse events was balanced across the treatment groups. Seven deaths were reported (one with medium-dose MF-IND-GLY, two with high-dose MF-IND-GLY, and four with high-dose MF-IND) during the study; none of these deaths was considered by the investigators to be caused by study drugs or other study-related factors. INTERPRETATION: Once-daily, single-inhaler MF-IND-GLY improved lung function versus ICS-LABA combinations (MF-IND and FLU-SAL) in patients with inadequately controlled asthma. The safety profile was similar across treatment groups. MF-IND-GLY therefore constitutes a good treatment option in these patients. FUNDING: Novartis Pharmaceuticals.
引用
- Kerstjens HAM, Maspero J, Chapman KR, et al. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. Lancet Respir Med. 2020. PMID: 32653074. doi:10.1016/S2213-2600(20)30190-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。